Outlook Therapeutics (NASDAQ:OTLK) Receives Buy Rating from HC Wainwright

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $30.00 price objective on the stock.

Several other research analysts also recently commented on the company. BTIG Research dropped their price target on Outlook Therapeutics from $50.00 to $9.00 and set a "buy" rating on the stock in a research report on Friday, November 29th. Chardan Capital reaffirmed a "neutral" rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $28.07.

Outlook Therapeutics Stock Up 1.8 %

Shares of OTLK traded up $0.04 during mid-day trading on Friday, hitting $2.23. 1,068,963 shares of the company's stock were exchanged, compared to its average volume of 1,067,862. The stock has a market cap of $55.55 million, a price-to-earnings ratio of -0.25 and a beta of 0.53. Outlook Therapeutics has a twelve month low of $0.87 and a twelve month high of $12.85. The firm has a fifty day moving average of $2.70 and a two-hundred day moving average of $5.35.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last released its quarterly earnings results on Friday, December 27th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.06. On average, equities analysts predict that Outlook Therapeutics will post -2.33 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Christensen King & Associates Investment Services Inc. acquired a new stake in Outlook Therapeutics in the third quarter worth about $55,000. AQR Capital Management LLC acquired a new position in Outlook Therapeutics in the second quarter valued at approximately $75,000. Barclays PLC boosted its stake in Outlook Therapeutics by 677.4% in the third quarter. Barclays PLC now owns 20,943 shares of the company's stock valued at $111,000 after acquiring an additional 18,249 shares during the last quarter. XTX Topco Ltd acquired a new stake in Outlook Therapeutics during the 3rd quarter worth $199,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Outlook Therapeutics during the 2nd quarter valued at $232,000. 11.20% of the stock is owned by institutional investors.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.